Early emergency department experience with 7‐day extended‐release injectable buprenorphine for opioid use disorder

Gail D'Onofrio, Jeanmarie Perrone, Kathryn F. Hawk, Ethan Cowan, Ryan McCormack, Edouard Coupet, Patricia H. Owens, Shara H. Martel, Kristen Huntley, Sharon L. Walsh, Michelle R. Lofwall, Andrew Herring, the ED‐INNOVATION Investigators

As the opioid overdose epidemic escalates, there is an urgent need for treatment innovations to address both patient and clinician barriers when initiating buprenorphine in the emergency department (ED). These include insurance status, logistical challenges such as the ability to fill a prescription, transportation, concerns regarding diversion, and availability of urgent referral sites. Extended-release buprenorphine (XR-BUP) preparations such as a new 7-day injectable could potentially solve some of these issues. We describe the pharmacokinetics of a new 7-day XR-BUP formulation and the feasibility of its use in the ED setting. We report our early experiences with this medication, (investigational drug CAM2038) in the context of an ongoing clinical trial entitled, Emergency Department-Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18 years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with opioid use disorder (OUD) who received the 7-day XR-BUP preparation in the ED between 6/2020-7/2023.